Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Safety Concerns Unlikely to Delay FDA Approval of Novartis' MS Drug Gilenia
Safety Concerns Unlikely to Delay FDA Approval of Novartis' MS Drug Gilenia
Safety Concerns Unlikely to Delay FDA Approval of Novartis' MS Drug Gilenia
Submitted by
admin
on June 2, 2010 - 8:25am
Source:
BNET Pharma
News Tags:
Novartis
MS
multiple sclerosis
Gilenia
Headline:
Safety Concerns Unlikely to Delay FDA Approval of Novartis' MS Drug Gilenia
Do Not Allow Advertisers to Use My Personal information
